(Reuters) -Amgen said on Wednesday there was no link between its experimental weight-loss drug and changes in bone density, a ...

The stocks of companies that make or are developing the new class of weight-loss and diabetes-management drugs were sharply lower Friday, after President-elect Donald Trump named Robert F. Kennedy Jr.

Amgen has spoken out about concerns related to bone mineral density (BMD) loss with its obesity candidate after an analyst’s comment caused a $12bn market wipe.

2 Dividend Stocks to Buy Hand Over Fist in November was originally published by The Motley Fool Their recent issues are ...

Big Pharma had plenty of drama to keep journalists busy this quarter, which painted an accurate portrait of the wild and ...

It's not just vaccine makers that are down following the announcement that former President Donald Trump has nominated Robert ...

AstraZeneca and Amgen announced that a Phase 3 trial of Tezspire (tezepelumab) showed a statistically significant and ...

While Novo Nordisk and Lilly are the undisputed leaders in weight management right now, a number of pharmaceutical companies ...

Over the past year, the question has been coming in from everywhere – from my patients and family members, from colleagues ...

Moderna stock and other vaccine shares tumbled Friday morning after Trump picked Kennedy to lead the Department of Health and ...

Tivic Health has completed enrolment in a study being conducted to finetune its non-invasive vagus nerve stimulation (VNS) ...

Regulators are reviewing what could become a multi-billion-dollar drug.